Epistem is a reputable global biotechnology company commercializing its world renowned expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases, inflammation and dermatological applications. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group’s expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.
Epistem’s Contract Research Division provides reliable in vitro and in vivo preclinical efficacy testing, advanced histology and immunohistochemistry services and cell biology expertise, in oncology (including leukemia), mucositis, inflammation (including inflammatory bowel disease [IBD] and Rheumatoid Arthritis [RA]), wound healing and skin care, with access to multiple imaging modalities.
The Personalized Medicine Division provides a highly-sensitive gene expression technology for discovery, development and translation of clinical biomarkers. The group has also developed Genedrive™, an innovative molecular diagnostic platform providing ‘point of care’ diagnosis.
Our Novel Therapies Division is identifying regulators of epithelial stem cells and tissues to develop therapeutics controlling cell production.